Benitec Biopharma Inc.: Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular Dys ...
Legislative immunity is a privilege in most states. A speeding ticket could change that in Arizona
That's because the Arizona Constitution shields state lawmakers from any civil process and arrest for anything but treason, ...
Microsoft: Owning The AI Stack Helps To Counter The DeepSeek Threat
Microsoft’s AI integration strengthens its position. Read why MSFT stock remains a solid buy despite the impact of DeepSeek’s ...
FVAL: A High-Tech Value Play With Risky Downside Exposure
Fidelity Value Factor ETF (FVAL) has a 0.15% expense ratio. It outperforms its peers, but faces higher risk. Read an ...
PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results
PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results Revenue of ...